The UK and US have concluded a significant bilateral deal that will keep no levies on UK drug shipments entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost spending on medicines through the National Health Service (NHS). This commitment ensures that duties on these crucial exports will remain at zero for a period of 36 months.
This development follows recent threats to significantly raise tariffs on patented pharmaceutical products, with potential rates discussed up to one hundred percent.
"This arrangement with the United Kingdom reinforces the international landscape for cutting-edge drugs and introduces long-overdue equity to U.S.–U.K. drug exports," an announcement declared.
Commercial Impact
Drugs are one of the Britain's most significant export categories to the United States, which is by far the primary buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months leading up to the third quarter, the UK sold medicines worth £11.1bn to the US. This figure accounted for nearly one-fifth of all goods exports in that span.
"This deal secures jobs, boosts capital expenditure and paves the way for the UK to establish itself as a global hub for medical research," a government official commented.
Key British Pledges
The deal involves several notable pledges from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise overall public funding on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must return to the NHS to prevent overspending will be limited at fifteen percent. Previously, refunds topped twenty percent.
Industry Background
This agreement comes amid a protracted tension between the drug companies and the ministers over drug pricing and regulatory access.
This friction were heightened by arguments that US consumers were charged several times more for the identical medicines than people in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial investments have been pledged toward US facilities.
One official acknowledged that the NHS had to increase expenditure on drugs, noting that its spending on drugs had declined as a share of its resources over the last ten years.
